CAF-specific miR-196a promotes NSCLC progression via C-C motif chemokine ligand 2 (CCL2) secretion by directly targeting ANXA1 (the gene for annexin-A1) which has anti-inflammatory properties [72]. The gene discussed is CCL2; the disease is non-small cell lung carcinoma.